TSE:AEZS Aeterna Zentaris (AEZS) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Aeterna Zentaris Stock (TSE:AEZS) 30 days 90 days 365 days Advanced Chart Remove Ads Get Aeterna Zentaris alerts:Sign Up Key Stats Today's Range N/A50-Day RangeC$5.00▼C$8.2952-Week Range N/AVolume1,232 shsAverage Volume1,137 shsMarket CapitalizationC$25.37 millionP/E RatioN/ADividend Yield2.79%Price TargetN/AConsensus RatingN/A Company OverviewAeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests in Canada, Switzerland, Ireland, Denmark, Germany, the United States, and internationally. Its lead product is Macrilen (macimorelin), an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of patients with adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as endocrinology and oncology indications; AEZS-150, a delayed clearance parathyroid hormone fusion polypeptide that is in preclinical trial for the treatment of chronic hypoparathyroidism; and AEZS-130 that is in preclinical trial for the treatment of amyotrophic lateral sclerosis. The company also has a license and research agreement with University of Wuerzburg to develop, manufacture, and commercialize AIM biologicals for the treatment of neuromyelitis optica spectrum disorder; and for pre-clinical development towards the potential treatment of Parkinson's disease. In addition, it has a license agreement with Consilient Health Ltd. and NK MEDITECH Ltd. for the development and commercialization of macimorelin; a distribution and commercialization agreement with Er-Kim Pharmaceuticals Bulgaria Eood for the commercialization of macimorelin for the diagnosis of growth hormone deficiency in children and adults; as well as The University of Sheffield, the United Kingdom for the development, manufacture, and commercialization of parathyroid hormone fusion polypeptides for the treatment of chronic hypoparathyroidism. Aeterna Zentaris Inc. was incorporated in 1990 and is headquartered in Toronto, Canada.Read More… Remove Ads Receive AEZS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Aeterna Zentaris and its competitors with MarketBeat's FREE daily newsletter. Email Address AEZS Stock News HeadlinesClosing Bell: Aeterna Zentaris Inc up on Monday (AEZS)July 30, 2024 | theglobeandmail.comAEZS:CA Aeterna Zentaris Inc.July 29, 2024 | seekingalpha.comTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to move your money now.April 2, 2025 | Porter & Company (Ad)Closing Bell: Aeterna Zentaris Inc flat on Friday (AEZS)July 20, 2024 | theglobeandmail.comCeapro's Q1 Net Loss Swells YoY, But Talks Up Benefits of Planned Aeterna MergerMay 29, 2024 | finance.yahoo.comCancer Cachexia Pipeline Insights Report, 2024 Featuring Emerging Drugs Macimorelin (AEterna Zentaris) and PF-06946860 (Pfizer)May 22, 2024 | finance.yahoo.comAeterna Zentaris Finalizes Some Details for Ceapro MergerMay 17, 2024 | finance.yahoo.comAEterna Zentaris: Top 10 Undervalued Healthcare Sector Stocks on TSX (AEZS)May 1, 2024 | theglobeandmail.comSee More Headlines AEZS Stock Analysis - Frequently Asked Questions How do I buy shares of Aeterna Zentaris? Shares of AEZS stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers. What other stocks do shareholders of Aeterna Zentaris own? Based on aggregate information from My MarketBeat watchlists, some other companies that Aeterna Zentaris investors own include Meta Platforms (META), Novavax (NVAX), Verizon Communications (VZ), Western Uranium & Vanadium (WUC), Air Canada (AC), Affirm (AFRM) and AutoZone (AZO). Industry, Sector and Symbol Stock ExchangeTSE SectorMedical Industry Biotechnology Sub-IndustryPharmaceutical Products Current SymbolTSE:AEZS CIKN/A Webwww.aezsinc.com Phone18439003223FaxN/AEmployees20Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)C($3.18) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeC$-18,050,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-81.71% Return on Assets-29.96% Debt Debt-to-Equity Ratio1.80 Current Ratio5.94 Quick Ratio9.37 Sales & Book Value Annual SalesC$2.37 million Price / Sales0.00 Cash FlowN/A Price / Cash Flow0.46 Book ValueC$10.68 per share Price / BookN/AMiscellaneous Outstanding Shares3,060,000Free FloatN/AMarket CapC$25.37 million OptionableNot Optionable Beta2.26 7 Top Nuclear Stocks To Buy NowNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free Report This page (TSE:AEZS) was last updated on 4/2/2025 by MarketBeat.com Staff From Our PartnersTrump Allies Confirm Exec Order 14024 Triggers Dollar CollapseExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | SponsoredBrace Yourself for Jeff Bezos’ “Amazon Helios”Jeff Bezos quietly backing world-changing tech (not AI) The Amazon founder is quietly advancing a radical t...Stansberry Research | SponsoredDOGE tax surpriseElon Musk's DOGE agents have some very strange plans for the IRS... Recently, it emerged that our tax auth...Altimetry | Sponsored“Amazon Coin” set to outperform BitcoinChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredUrgent Bitcoin alert for RIGHT NOWFormer billion-dollar hedge fund manager Larry Benedict has released the most incredible presentation of his 4...Brownstone Research | SponsoredTrump’s betrayal exposed Fair warning: this will not make for easy viewing. Especially if you voted for Trump, put your faith in hi...Porter & Company | SponsoredNew “Trump” currency proposed in DCYou’ve no doubt heard Trump’s rally cry: Make America Great Again. But recently the President made a big ch...Paradigm Press | SponsoredOil Surge Predicted... But Are You Ready?Do you own oil and gas stocks? Or are you thinking about buying some? But it's NOT oil stocks, futures, or ...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aeterna Zentaris Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aeterna Zentaris With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.